Skip to main content

Table 1 Transition probabilities for initial phase of model (between baseline and 12 months)

From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

  

STANDARD OF CARE STRATEGY

Health state at 1-year

HS1

HS2

HS3

HS4

HS5

Health state at baseline

HS1

1.00

0.00

0.00

0.00

0.00

HS2

0.25

0.50

0.00

0.25

0.00

HS3

0.00

0.00

1.00

0.00

0.00

HS4

0.00

0.00

1.00

0.00

0.00

HS5

0.00

0.00

0.00

1.00

0.00

  

VN STRATEGY

Health state at 1-year

HS1

HS2

HS3

HS4

HS5

Health state at baseline

HS1

1.00

0.00

0.00

0.00

0.00

HS2

0.83

0.17

0.00

0.00

0.00

HS3

0.50

0.50

0.00

0.00

0.00

HS4

0.50

0.00

0.25

0.25

0.00

HS5

0.00

0.50

0.00

0.25

0.25

  1. All visual acuity scores measured by logMAR (VA) and visual function (VF) scores measured by sum total degrees, are calculated as the average of both eyes.
  2. HS1, moderate visual impairment (patient either has VA<1 or VF>240; and does not belong to a worse health state); HS2, severe visual impairment (patient either has VA≥1 and VA<1.4, or VF≤240 and VF>144; and does not belong to a worse health state); HS3, profound visual impairment (patient either has VA≥1.4 and VA<1.8, or VF≤144 and VF>48; and does not belong to a worse health state); HS4, counting fingers (patient either has VA≥1.8 and VA<3, or VF≤48; and does not belong to a worse health state); HS5, hand motion, light perception to no light perception (patient has VA≥3, or indications of hand motion, “light perception”, or “no light perception” across both eyes)
  3. BSC best supportive care, TP transition probability, VN voretigene neparvovec